Sulthiame

ERS Congress 2024 discussed AI-powered robots in respiratory care, IPF trial failures, lung function decline in fibrotic diseases, ILD risk factors in rheumatic patients, and an epilepsy drug's potential in treating OSA.

Research on sleep apnea includes CPAP machines, mouth guards, and throat exercises. Lilly's tirzepatide showed significant AHI reduction in phase 3 trials. Epilepsy drug sulthiame also showed promise in sleep apnea trials. Apnimed's AD109 targets hypoglossal motor neurons, improving airway signals. Gut microbiome changes linked to sleep apnea severity suggest patient-specific therapies.

Sulthiame, an epilepsy drug, reduced OSA symptoms in a clinical trial, decreasing AHI3a by 17.8-39.9% and AHI4 by nearly 50%. Patients reported less daytime sleepiness and improved oxygen levels. Sulthiame is not approved in the US but offers an alternative to CPAP machines, with mild to moderate side effects. A phase III study is needed to confirm its benefits.

A European epilepsy drug, sulthiame, shows potential as a treatment for sleep apnea, reducing breathing pauses and increasing blood oxygen levels in a clinical trial. Sulthiame, not approved in the U.S., targets the respiratory system by inhibiting carbonic anhydrase, stimulating upper airway muscles. Further trials are needed to confirm its benefits and long-term effects.

Sulthiame, an epilepsy drug used in Europe, showed potential in treating sleep apnea, reducing breathing pauses and increasing blood oxygen levels in a clinical trial. However, further trials are needed to confirm its efficacy and safety.